TRPV6 Calcium Channel Targeting by Antibodies Raised against Extracellular Epitopes Induces Prostate Cancer Cell Apoptosis.
Aurélien HaustrateGeorge ShapovalovCorentin SprietClément CordierArtem KondratskyiLucile NoyerFrançois FoulquierNatalia PrevarskayaV'yacheslav Lehen'kyiPublished in: Cancers (2023)
The TRPV6 calcium channel is known to be up-regulated in various tumors. The efforts to target the TRPV6 channel in vivo are still ongoing to propose an effective therapy against cancer. Here, we report the generation of two antibodies raised against extracellular epitopes corresponding to the extracellular loop between S1 and S2 (rb79) and the pore region (rb82). These antibodies generated a complex biphasic response with the transient activation of the TRPV6 channel. Store-operated calcium entry was consequently potentiated in the prostate cancer cell line LNCaP upon the treatment. Both rb79 and rb82 antibodies significantly decreased cell survival rate in a dose-dependent manner as compared to the control antibodies of the same isotype. This decrease was due to the enhanced cell death via apoptosis revealed using a sub-G1 peak in a cell cycle assay, TUNEL assay, and a Hoechst staining, having no effects in the PC3M trpv6-/- cell line. Moreover, all TUNEL-positive cells had TRPV6 membrane staining as compared to the control antibody treatment where TRPV6-positive cells were all TUNEL negative. These data clearly demonstrate that TRPV6 channel targeting using rb79 and rb82 antibodies is fatal and may be successfully used in the anticancer therapies.
Keyphrases
- prostate cancer
- cell cycle arrest
- neuropathic pain
- cell death
- cell cycle
- induced apoptosis
- cell proliferation
- radical prostatectomy
- endoplasmic reticulum stress
- transcription factor
- squamous cell carcinoma
- cancer therapy
- high throughput
- stem cells
- spinal cord injury
- pi k akt
- single cell
- quality improvement
- signaling pathway
- cerebral ischemia
- deep learning